Shivalik Rasayan Limited

Delhi, India Founded: 1979 • Age: 47 yrs Listed
Shivalik Rasayan Limited is engaged in manufacturing APIs and agrochemicals.

About Shivalik Rasayan Limited

Shivalik Rasayan Limited is a publicly listed company based in Delhi (India) founded in 1979. Shivalik Rasayan Limited is engaged in manufacturing APIs and agrochemicals. It operates on a B2B2C and Reseller / Distribution model. The company has 341 employees. Its Indian entity Shivalik Rasayan Limited reported revenue of β‚Ή372 Cr. Shivalik Rasayan Limited offers products and services including Active Pharmaceutical Ingredients (APIs), Agrochemicals, and Specialty Chemicals. Its focus areas include Pharmaceuticals, Active Pharmaceutical Ingredients, Agriculture and Agrochemicals.

Company details

Shivalik Rasayan Limited is involved in the production of active pharmaceutical ingredients (APIs) and agrochemicals. Operations are focused on oncology and non-oncology APIs, alongside specialty chemicals for industrial use. Facilities are established in compliance with global standards like USFDA and EDQM. The company is also dedicated to research and development in custom manufacturing. Solutions are provided across healthcare, agriculture, and chemical sectors. Innovation is emphasized to enhance product effectiveness and sustainability.

  • Headquarters Delhi, India
  • Employees 341
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website shivalikrasayan.com
  • Legal Name Shivalik Rasayan Ltd
Key Metrics
  • Market Cap
    ₹489 Cr

    SHIVALIK · NSE

  • Share Price
    ₹291.30

    -4.54% today

  • Revenue
    ₹368 Cr

    FY 2025-26 · +18.0% YoY

  • EBITDA
    ₹45.76 Cr

    Margin 12.4%

  • Net Profit
    ₹12.13 Cr

    FY 2025-26 · -27.4% YoY

  • P/E (TTM)
    35.8x

    P/B 0.8x

  • ROE
    3.2%

    ROCE 4.7%

  • Debt / Equity
    0.20

    Interest cover 38.6x

  • Employee Count
    341

Products & Services of Shivalik Rasayan Limited

Shivalik Rasayan Limited offers a comprehensive portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Agrochemicals, and Specialty Chemicals.

Active Pharmaceutical Ingredients (APIs)
Pharmaceuticals

Manufactured APIs adhering to global regulatory standards.

Agrochemicals
Agriculture

Developed agrochemicals for sustainable and effective farming.

Specialty Chemicals
Chemicals

Innovated specialty chemicals for various industrial applications.

Board of directors of Shivalik Rasayan Limited (Shivalik Rasayan Limited)

Shivalik Rasayan Limited is the primary company behind Shivalik Rasayan Limited. The board of Shivalik Rasayan Limited currently have 10 directors; the longest-serving is Suresh Kumar Singh, appointed in 1997. 12 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Suresh Kumar Singh
DIN 00318015
Whole-time director15 Dec 199728 yrs 11 moShivalik Rasayan Limited
Rahul Bishnoi
DIN 00317960
Director23 Feb 200224 yrs 8 moShivalik Rasayan Limited
Ashwani Kumar Sharma
DIN 00325634
Director18 Jul 200323 yrs 3 moShivalik Rasayan Limited
Sumita Dwivedi
DIN 08218640
Director13 Nov 20188 yrsShivalik Rasayan Limited
Vimal Kumar Shrawat
DIN 08274190
Managing Director17 Nov 20187 yrs 11 moShivalik Rasayan Limited
Sangeeta Bishnoi
DIN 08288998
Director11 Feb 20197 yrs 9 moShivalik Rasayan Limited
Ravi Kumar Bansal
DIN 08462513
Director14 Aug 20197 yrs 3 moShivalik Rasayan Limited
Shaival Saurabh
DIN 01971944
Director13 Aug 20242 yrs 3 moShivalik Rasayan Limited
Sham Goel
DIN 02183287
Director13 Aug 20242 yrs 3 moShivalik Rasayan Limited
Ramit Madan
DIN 08071919
Director13 Aug 20242 yrs 3 moShivalik Rasayan Limited

IPO & Listings of Shivalik Rasayan Limited

Shivalik Rasayan Limited is a publicly listed company on the NSE with ticker symbol SHIVALIK in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date09 Dec 2021
  • Listed onNSE: SHIVALIK
  • Listed entityShivalik Rasayan Ltd
  • Exchange sectorProcess industries
  • ISININE788J01021
  • Share price₹356.80 (+0.1% on the day) · 2026-10-14
  • Market capitalisation₹562 Cr
  • Price to earnings40.9
  • EPS (diluted, trailing year)₹8.72
  • Dividend yield0.14%
  • Volume (last session)10,017

Financials of Shivalik Rasayan Limited

Exchange-reported figures of Shivalik Rasayan Limited, the listed company behind Shivalik Rasayan Limited (NSE: SHIVALIK).

Financial Highlights

FY 2025-26 Β· Consolidated
Revenue
₹368 Cr
+18.0% YoY
EBITDA
₹45.76 Cr
+11.9% YoY
Profit After Tax
₹12.13 Cr
-27.4% YoY
Net Worth
₹599 Cr
+11.7% YoY
Total Assets
₹725 Cr
+12.6% YoY
Total Debt
₹123 Cr
+17.2% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue368312273234215198186
Revenue growth+18.0%+14.2%+16.4%+9.2%+8.7%+6.1%-
EBITDA45.7640.8940.6343.4647.3338.4128.94
EBITDA margin+12.4%+13.1%+14.9%+18.5%+22.0%+19.4%+15.5%
Profit before tax21.4723.4123.2731.6736.9728.9226.70
Net profit12.1316.7012.7120.7625.6017.5914.06
Net profit margin+3.3%+5.4%+4.7%+8.9%+11.9%+8.9%+7.6%
EPS (β‚Ή)7.7110.608.1714.3217.6712.7710.16
Balance sheet
Total assets725644586479405290261
Net worth599536508419287179176
Total debt12310576.0857.7138.4328.6610.25
Cash & bank34.3727.9737.7430.6770.764.779.04
Net working capital28922518816315757.5590.57
Cash flow
Cash from operations(33.96)(9.20)(8.08)(18.95)11.1358.775.72
Cash from investing(21.23)(21.11)(74.31)(70.77)(23.36)(65.02)(102)
Cash from financing61.5820.5489.4549.6378.211.9810.29
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue10196.3410382.0493.8489.3169.3985.31
Revenue growth (YoY)+7.2%+7.9%+48.2%-3.8%+13.8%+19.7%--
Other income0.010.971.921.180.390.605.711.60
EBITDA14.8411.1912.4310.3312.0310.985.7513.31
EBITDA margin+14.7%+11.6%+12.1%+12.6%+12.8%+12.3%+8.3%+15.6%
Depreciation4.614.414.165.064.734.822.784.84
Interest3.452.082.462.312.222.622.712.26
Profit before tax6.795.677.734.145.474.145.977.81
Tax1.401.160.550.461.171.320.790.89
Net profit5.394.517.183.684.302.825.186.92
EPS (β‚Ή)2.302.162.871.711.931.022.623.39
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue17014993.6893.5899.3084.8760.77
Revenue growth+14.1%+59.3%+0.1%-5.8%+17.0%+39.7%-
EBITDA26.3626.4717.1319.1223.2418.749.47
EBITDA margin+15.5%+17.7%+18.3%+20.4%+23.4%+22.1%+15.6%
Profit before tax9.4813.5310.2114.6318.8712.538.72
Net profit8.1613.878.6415.1219.3612.678.76
Net profit margin+4.8%+9.3%+9.2%+16.2%+19.5%+14.9%+14.4%
EPS (β‚Ή)5.198.805.5510.4213.369.206.35
Balance sheet
Total assets479470430331289192168
Net worth405398374291273180168
Total debt73.5970.9554.8539.8015.3311.330.27
Cash & bank3.1024.2122.959.8966.930.885.95
Net working capital11011196.8770.5194.608.4539.66
Cash flow
Cash from operations(1.26)(1.04)(1.36)(12.66)7.0246.00(7.08)
Cash from investing(18.19)(19.71)(68.74)(64.89)(16.50)(61.28)(64.65)
Cash from financing(1.66)22.0183.1620.5175.5210.22(8.77)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue45.8048.4442.1735.1346.6746.2639.7840.16
Revenue growth (YoY)-1.9%+4.7%+6.0%-12.5%+23.8%+46.5%--
Other income0.020.100.180.640.020.130.481.46
Total expenses39.6441.5835.1829.1839.7939.9032.4233.56
EBITDA6.166.866.995.956.886.367.366.60
EBITDA margin+13.4%+14.2%+16.6%+16.9%+14.7%+13.7%+18.5%+16.4%
Depreciation2.732.632.433.242.873.012.302.63
Interest1.761.252.071.341.231.462.061.50
Profit before tax1.693.082.672.012.802.023.483.93
Tax0.390.43(0.06)(0.02)0.600.790.16(0.07)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 16 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue10196.3410382.0493.8489.3169.3985.31
Revenue growth (YoY)+7.2%+7.9%+48.2%-3.8%+13.8%+19.7%--
Other income0.010.971.921.180.390.605.711.60
EBITDA14.8411.1912.4310.3312.0310.985.7513.31
EBITDA margin+14.7%+11.6%+12.1%+12.6%+12.8%+12.3%+8.3%+15.6%
Depreciation4.614.414.165.064.734.822.784.84
Interest3.452.082.462.312.222.622.712.26
Profit before tax6.795.677.734.145.474.145.977.81
Tax1.401.160.550.461.171.320.790.89
Net profit5.394.517.183.684.302.825.186.92
EPS (β‚Ή)2.302.162.871.711.931.022.623.39
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue368312273234215198186
Revenue growth+18.0%+14.2%+16.4%+9.2%+8.7%+6.1%-
Other income4.088.313.984.663.711.133.14
Total expenses322271232191167159157
Employee cost0.0054.0245.6933.0926.3718.1113.66
EBITDA45.7640.8940.6343.4647.3338.4128.94
EBITDA margin+12.4%+13.1%+14.9%+18.5%+22.0%+19.4%+15.5%
Depreciation18.7715.7712.3811.6011.018.583.51
Interest9.6010.028.964.853.062.041.87
Profit before tax21.4723.4123.2731.6736.9728.9226.70
Tax3.512.985.151.832.714.274.65
Net profit12.1316.7012.7120.7625.6017.5914.06
Net profit margin+3.3%+5.4%+4.7%+8.9%+11.9%+8.9%+7.6%
EPS (β‚Ή)7.7110.608.1714.3217.6712.7710.16
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital7.887.887.787.247.246.896.89
Reserves & surplus591528496397270172169
Shareholders' funds (net worth)599536508419287179176
Minority interest0.000.000.000.0077.4980.4273.27
Secured loans23.3816.5023.9713.0138.4328.6610.25
Unsecured loans99.4188.2352.1144.700.000.000.00
Total debt12310576.0857.7138.4328.6610.25
Total liabilities725644586479405290261
Assets
Gross block44242528728027124782.63
Net block33533721421822121051.57
Capital work in progress0.000.0011757.343.300.00102
Investments0.000.000.000.000.000.000.00
Inventories14711810274.9938.149.8120.12
Sundry debtors11596.1286.7484.7770.0068.8458.17
Cash & bank balances34.3727.9737.7430.6770.764.779.04
Loans & advances85.7072.8567.6071.1260.9947.2970.28
Total current assets382315294262240131158
Total current liabilities93.5789.9710698.8783.1173.1667.04
Net working capital28922518816315757.5590.57
Total assets725644586479405290261
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash27.9737.7430.6770.764.779.0494.97
Net cash from operating activities(33.96)(9.20)(8.08)(18.95)11.1358.775.72
Net cash from investing activities(21.23)(21.11)(74.31)(70.77)(23.36)(65.02)(102)
Net cash from financing activities61.5820.5489.4549.6378.211.9810.29
Net change in cash6.40(9.77)7.07(40.09)65.99(4.26)(85.93)
Closing cash34.3727.9737.7430.6770.764.779.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+18.0%+14.2%+16.4%+9.2%+8.7%+6.1%-
EBITDA growth+11.9%+0.6%-6.5%-8.2%+23.2%+32.7%-
PBT growth-14.5%+8.0%-26.5%-14.3%+27.8%+8.3%+2.0%
Net income growth-27.4%+31.4%-38.8%-18.9%+45.5%+25.1%-
Revenue CAGR (3Y)+16.2%+13.2%+11.4%+8.0%+8.0%+8.4%+14.7%
EBITDA CAGR (3Y)+2.7%-4.8%+1.9%+14.5%+25.9%+16.8%+16.4%
Profitability & leverage
Net income margin+4.9%+7.1%+6.6%+12.7%+16.0%+12.5%+11.8%
Return on capital employed+4.7%+5.4%+6.1%+9.1%+14.9%+15.6%+15.2%
Return on net worth+3.2%+4.2%+3.9%+8.4%+14.7%+13.9%+12.9%
Debt / equity0.200.170.140.140.140.110.09
Long-term debt / equity0.040.040.040.030.040.040.02
Interest cover38.6233.1131.7215.228.436.847.35
Efficiency & per share
Fixed asset turnover0.850.880.960.850.831.202.46
Inventory turnover2.782.843.094.148.9613.208.95
Debtors turnover3.483.413.183.033.093.113.38
EPS (β‚Ή)7.8710.608.1714.3217.6712.7710.16
Dividend per share (β‚Ή)0.500.500.500.500.500.500.25
Book value per share (β‚Ή)380.37340.46324.05278.69191.54129.96127.93
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue45.8048.4442.1735.1346.6746.2639.7840.16
Revenue growth (YoY)-1.9%+4.7%+6.0%-12.5%+23.8%+46.5%--
Other income0.020.100.180.640.020.130.481.46
Total expenses39.6441.5835.1829.1839.7939.9032.4233.56
EBITDA6.166.866.995.956.886.367.366.60
EBITDA margin+13.4%+14.2%+16.6%+16.9%+14.7%+13.7%+18.5%+16.4%
Depreciation2.732.632.433.242.873.012.302.63
Interest1.761.252.071.341.231.462.061.50
Profit before tax1.693.082.672.012.802.023.483.93
Tax0.390.43(0.06)(0.02)0.600.790.16(0.07)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue17014993.6893.5899.3084.8760.77
Revenue growth+14.1%+59.3%+0.1%-5.8%+17.0%+39.7%-
Other income0.962.061.652.201.990.381.20
Total expenses14412376.5574.4676.0666.1351.30
Employee cost25.8623.1516.6212.9411.889.114.14
EBITDA26.3626.4717.1319.1223.2418.749.47
EBITDA margin+15.5%+17.7%+18.3%+20.4%+23.4%+22.1%+15.6%
Depreciation11.558.705.285.245.246.061.01
Interest6.296.303.291.451.120.530.94
Profit before tax9.4813.5310.2114.6318.8712.538.72
Tax1.32(0.34)1.57(0.49)(0.49)(0.14)(0.04)
Net profit8.1613.878.6415.1219.3612.678.76
Net profit margin+4.8%+9.3%+9.2%+16.2%+19.5%+14.9%+14.4%
EPS (β‚Ή)5.198.805.5510.4213.369.206.35
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital7.887.887.787.247.246.896.89
Reserves & surplus397390363271256173161
Shareholders' funds (net worth)405398374291273180168
Secured loans27.7623.0932.3018.414.554.700.26
Unsecured loans45.8347.8622.5521.3910.786.630.01
Total debt73.5970.9554.8539.8015.3311.330.27
Total liabilities479470430331289192168
Assets
Gross block29828615014914613224.89
Net block25025012212612812017.88
Capital work in progress0.000.0011757.343.300.0061.24
Investments81.0974.4773.4364.9455.0153.4039.32
Inventories76.7955.5642.4529.9311.134.613.16
Sundry debtors33.3127.2231.4819.526.7816.298.21
Cash & bank balances3.1024.2122.959.8966.930.885.95
Loans & advances45.1445.8541.7544.5338.2117.4940.51
Total current assets15815313910412339.2757.83
Total current liabilities48.7041.8541.7633.3628.4530.8218.17
Net working capital11011196.8770.5194.608.4539.66
Total assets479470430331289192168
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash24.2122.959.8966.930.885.9586.45
Net cash from operating activities(1.26)(1.04)(1.36)(12.66)7.0246.00(7.08)
Net cash from investing activities(18.19)(19.71)(68.74)(64.89)(16.50)(61.28)(64.65)
Net cash from financing activities(1.66)22.0183.1620.5175.5210.22(8.77)
Net change in cash(21.11)1.2613.06(57.04)66.05(5.06)(80.51)
Closing cash3.1024.2122.959.8966.930.885.95
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.1%+59.3%+0.1%-5.8%+17.0%+39.7%-
EBITDA growth-0.4%+54.5%-10.4%-17.7%+24.0%+97.9%-
PBT growth-29.9%+32.5%-30.2%-22.5%+50.6%+43.7%+0.9%
Net income growth-41.2%+60.5%-42.9%-21.9%+52.8%+44.6%-
Revenue CAGR (3Y)+22.1%+14.5%+3.4%+15.5%+27.5%+24.8%+14.1%
EBITDA CAGR (3Y)+11.3%+4.4%-3.0%+26.4%+54.9%+36.9%+11.8%
Profitability & leverage
Net income margin+4.8%+9.3%+9.2%+16.2%+19.5%+14.9%+14.4%
Return on capital employed+3.3%+4.4%+3.6%+5.2%+8.3%+7.3%+5.7%
Return on net worth+2.0%+3.6%+2.6%+5.4%+8.5%+7.3%+5.4%
Debt / equity0.180.160.140.100.060.030.03
Long-term debt / equity0.040.050.050.030.020.010.02
Interest cover42.4735.4527.7610.456.224.1811.11
Efficiency & per share
Fixed asset turnover0.580.680.630.630.711.082.57
Inventory turnover2.573.052.594.5612.6221.8512.94
Debtors turnover5.625.083.677.128.616.937.20
EPS (β‚Ή)5.198.805.5510.4213.369.206.35
Dividend per share (β‚Ή)0.500.500.500.500.500.500.25
Book value per share (β‚Ή)256.91252.47238.23191.82181.90130.63121.67

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Shivalik Rasayan Limited (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Shivalik Rasayan Limited

Shivalik Rasayan Ltd: Files Drug Master File For Avapritinib API With USFDA; This Product Is For Treating Gastrointestinal Stromal Tumors; Ayvakit Is Expected To Make 700 Million USD In Revenue By 2025.
Exchange Update β€’ 14 days ago
Shivalik Rasayan to declare Quarterly Result
India Infoline β€’ 1 year ago
Premium access

Complete news archive for Shivalik Rasayan Limited

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Shivalik Rasayan Limited

Shivalik Rasayan Limited was founded in 1979.

Shivalik Rasayan Limited is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.

Shivalik Rasayan Limited has 341 employees.

The primary company behind Shivalik Rasayan Limited, Shivalik Rasayan Limited, reported revenue of β‚Ή372 Cr for FY 2026, up 18% year on year.

Shivalik Rasayan Limited is involved in the production of active pharmaceutical ingredients (APIs) and agrochemicals. Operations are focused on oncology and non-oncology APIs, alongside specialty chemicals for industrial use. Facilities are established in compliance with global standards like USFDA and EDQM. The company is also dedicated to research and development in custom manufacturing. Solutions are provided across healthcare, agriculture, and chemical sectors. Innovation is emphasized to enhance product effectiveness and sustainability.

Shivalik Rasayan Limited offers Active Pharmaceutical Ingredients (APIs), Agrochemicals, and Specialty Chemicals.

Yes, Shivalik Rasayan Limited is publicly traded on NSE under the ticker symbol SHIVALIK.

Shivalik Rasayan Limited operates through Shivalik Rasayan Limited.

The legal entities of Shivalik Rasayan Limited currently have 12 directors, including Sangeeta Bishnoi, Sumita Dwivedi, Ravi Kumar Bansal and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available